Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,910 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Symposium: clinical study of acid-bace balance].
Yamashita K, Kanaoka T, Momose T, Mimura H, Hasegawa H. Yamashita K, et al. Among authors: hasegawa h. Iryo. 1970;24:Suppl:31-5. Iryo. 1970. PMID: 5510965 Japanese. No abstract available.
Protective Effect of Conditioned Medium of Immortalized Human Stem Cells from Exfoliated Deciduous Teeth Against Hair Graying Caused by X-Ray Irradiation via Its Antioxidative Activity.
Katahira Y, Horio E, Yamaguchi N, Sonoda J, Yamagishi M, Miyakawa S, Murakami F, Hasegawa H, Mizoguchi I, Yoshimoto T. Katahira Y, et al. Among authors: hasegawa h. Antioxidants (Basel). 2025 Jan 18;14(1):109. doi: 10.3390/antiox14010109. Antioxidants (Basel). 2025. PMID: 39857443
Long-term impact of molecular epidemiology shifts of methicillin-resistant Staphylococcus aureus on severity and mortality of bloodstream infection.
Kaku N, Ishige M, Yasutake G, Sasaki D, Ota K, Mitsumoto-Kaseida F, Kosai K, Hasegawa H, Izumikawa K, Mukae H, Yanagihara K. Kaku N, et al. Among authors: hasegawa h. Emerg Microbes Infect. 2025 Dec;14(1):2449085. doi: 10.1080/22221751.2024.2449085. Epub 2025 Jan 9. Emerg Microbes Infect. 2025. PMID: 39789882 Free PMC article.
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, Takahashi M, Tsurutani J, Iwatani T, Kitada M, Tada H, Mori N, Higuchi T, Iwasa T, Araki K, Koizumi K, Hasegawa H, Uchida Y, Morita S, Masuda N. Yamashita T, et al. Among authors: hasegawa h. J Clin Oncol. 2025 Jan 9:JCO2401888. doi: 10.1200/JCO-24-01888. Online ahead of print. J Clin Oncol. 2025. PMID: 39787453
3,910 results